Neuronetics Responds to Activist Investor's Call for Higher Valuation

Event summary

  • Neuronetics issued a response on April 7, 2026, to a public letter from Pointillist Family Office's Jorey Chernett, who criticized the company's valuation.
  • The board acknowledged the letter and agreed that the current valuation does not reflect the company's business strength.
  • Neuronetics operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy and SPRAVATO for mental health disorders.
  • The company's NeuroStar Advanced Therapy System is FDA-cleared for multiple neurohealth conditions, including major depressive disorder (MDD).

The big picture

Neuronetics' response to Pointillist Family Office highlights the growing tension between activist investors and medical technology companies over valuation. The engagement reflects broader trends in shareholder activism, where investors push for higher valuations by leveraging strategic insights. Neuronetics' focus on neurohealth disorders positions it within a rapidly evolving mental health sector, where non-drug treatments like TMS are gaining traction. The company's ability to align its valuation with its business strength will be a key factor in sustaining investor confidence.

What we're watching

Valuation Realignment
Whether Neuronetics can execute strategic priorities to close the valuation gap identified by Pointillist Family Office.
Shareholder Dynamics
The extent of future engagement between Neuronetics' board and activist investors like Pointillist Family Office.
Therapeutic Expansion
The pace at which Neuronetics expands the use of NeuroStar Advanced Therapy beyond MDD into other neurohealth conditions.